Effects of Troglitazone on HepG2 Viability and Mitochondrial Function
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Troglitazone (TRO), a member of the thiazolidinedione class of drugs, has been associated with hepatotoxicity in patients. The following in vitro study was conducted to investigate the effects of TRO on mitochondrial function and viability in a human hepatoma cell line, HepG2. TRO induced a concentration- and time-dependent increase in cell death, as measured by lactate dehydrogenase release. Exposure to 50 or 100 micro M TRO produced total loss of cell viability within 5 h. Preincubation of HepG2 cells with P450 inhibitors did not significantly protect against TRO-induced cell death suggesting that P450 metabolism was not required to induce cell death. Preincubation with the mitochondrial permeability transition inhibitor, cyclosporin A, provided complete protection against TRO-induced cell death. Our results also indicated that TRO produced concentration-dependent decreases in cellular ATP levels and mitochondrial membrane potential (MMP). Ultrastructural analysis demonstrated that TRO induced mitochondrial changes at concentrations of > or =10 micro M after 2 h. Decreased MMP and altered mitochondrial morphology occurred at time points that preceded cell death and at sublethal concentrations of TRO. These observations in HepG2 cells suggest that TRO disrupts mitochondrial function, leading to mitochondrial permeability transition and cell death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.
Caldwell, S. H., Hespenheide, E. E., Redick, J. A., Iezzoni, J. C., Battle, E. H., & Sheppard, B. L. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03553.x · Cited by 394
Kassahun, K., Pearson, P. G., Tang, W., McIntosh, I., Leung, K., Elmore, C., Dean, D., Wang, R., Doss, G., & Baillie, T. A. (2001) · Chemical Research in Toxicology · doi:10.1021/tx000180q · Cited by 311 · cited 10×
“(1993) concluded that CYP3A7 was exclusively expressed in HepG2 cells.”
BackgroundInfluentialDE PINIEUX, G., CHARIOT, P., AMMI‐SAÏD, M., LOUARN, F., LEJONC, J. L., ASTIER, A., JACOTOT, B., & GHERARDI, R. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.04178.x · Cited by 262
Cited by
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Hewitt, N. J., Gómez Lechón, M. J., Houston, J. B., Hallifax, D., Brown, H. S., Maurel, P., Kenna, J. G., Gustavsson, L., Lohmann, C., Skonberg, C., et al. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530601093489 · Cited by 735
The significance of mitochondrial toxicity testing in drug development
Dykens, J. A., & Will, Y. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.07.013 · Cited by 416
Receptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key?
Feinstein, D. L., Spagnolo, A., Akar, C., Weinberg, G., Murphy, P., Gavrilyuk, V., & Russo, C. D. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.03.033 · Cited by 275
The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR)
Peraza, M. A., Burdick, A. D., Marin, H. E., Gonzalez, F. J., & Peters, J. M. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj062 · Cited by 254
Metadata
- Authors
- Tirmenstein, M. A.
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-09-01
- Volume
- 69
- Issue
- 1
- Pages
- 131-138
- ISSN
- 1096-0929 (ISSN-L)
- OpenAlex
- W2113744933
- Cited by
- 110
- References
- 3
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.